A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

scientific article

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/J.1753-5174.2007.00002.X
P932PMC publication ID2817438
P698PubMed publication ID20157362
P5875ResearchGate publication ID41435743

P50authorChristopher P CannonQ90608635
P2093author name stringCong Chen
John Viscusi
Peter M Dibattiste
Sean P Curtis
Tuli Ahmed
P2860cites workPrediction of Coronary Heart Disease Using Risk Factor CategoriesQ22241923
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsQ24546221
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)Q27860959
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupQ28138338
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseQ28181305
C-reactive protein and other inflammatory risk markers in acute coronary syndromesQ28195425
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysisQ28200524
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialQ28217835
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonQ28218927
???Q28199855
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesQ29619614
Intensive versus moderate lipid lowering with statins after acute coronary syndromesQ29619716
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionQ29620087
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?Q33678964
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statementQ33993977
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesQ34245387
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studiesQ34469221
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.Q34575707
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonQ34582722
Clinical application of C-reactive protein for cardiovascular disease detection and preventionQ35054464
Old and new cardiovascular risk factors: from unresolved issues to new opportunitiesQ35603920
Established and emerging plasma biomarkers in the prediction of first atherothrombotic eventsQ35822621
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary eventsQ40646293
A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health StudyQ40818460
Influence of fibrinogen on cardiovascular diseaseQ41635547
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsQ44216708
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysisQ45088909
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.Q51574876
Fibrinogen and risk of cardiovascular disease. The Framingham Study.Q52588834
Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine StudyQ74196327
EtoricoxibQ80471891
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectplaceboQ269829
biomarkerQ864574
P304page(s)4-13
P577publication date2008-07-01
P1433published inArchives of Drug InformationQ15753799
P1476titleA Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo
P478volume1